222 related articles for article (PubMed ID: 38714074)
1. Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment.
Acharya SS; Kundu CN
Cancer Treat Rev; 2024 Jun; 127():102749. PubMed ID: 38714074
[TBL] [Abstract][Full Text] [Related]
2. Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis.
Yang M; Mu Y; Yu X; Gao D; Zhang W; Li Y; Liu J; Sun C; Zhuang J
Biomed Pharmacother; 2024 Jul; 176():116783. PubMed ID: 38796970
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment and angiogenesis.
Nyberg P; Salo T; Kalluri R
Front Biosci; 2008 May; 13():6537-53. PubMed ID: 18508679
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
Mittal K; Ebos J; Rini B
Semin Oncol; 2014 Apr; 41(2):235-51. PubMed ID: 24787295
[TBL] [Abstract][Full Text] [Related]
5. Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential.
Ruan L; Zhang S; Chen X; Liang W; Xie Q
Pathol Res Pract; 2022 Aug; 236():153956. PubMed ID: 35700578
[TBL] [Abstract][Full Text] [Related]
6. The role of microenvironment in tumor angiogenesis.
Jiang X; Wang J; Deng X; Xiong F; Zhang S; Gong Z; Li X; Cao K; Deng H; He Y; Liao Q; Xiang B; Zhou M; Guo C; Zeng Z; Li G; Li X; Xiong W
J Exp Clin Cancer Res; 2020 Sep; 39(1):204. PubMed ID: 32993787
[TBL] [Abstract][Full Text] [Related]
7. Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy.
Mohammadi P; Yarani R; Rahimpour A; Ranjbarnejad F; Mendes Lopes de Melo J; Mansouri K
Drug Metab Rev; 2022 Nov; 54(4):386-400. PubMed ID: 36031813
[TBL] [Abstract][Full Text] [Related]
8. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J; Mortezaee K
Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
[TBL] [Abstract][Full Text] [Related]
10. Role of the tumor stroma in resistance to anti-angiogenic therapy.
Huijbers EJ; van Beijnum JR; Thijssen VL; Sabrkhany S; Nowak-Sliwinska P; Griffioen AW
Drug Resist Updat; 2016 Mar; 25():26-37. PubMed ID: 27155374
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
12. Targeting the tumor stroma in cancer therapy.
Anton K; Glod J
Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-mediated effects on angiogenesis in solid tumors.
Martens B; Drebert Z
J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109
[TBL] [Abstract][Full Text] [Related]
14. The tumor microenvironment and its contribution to tumor evolution toward metastasis.
Lorusso G; Rüegg C
Histochem Cell Biol; 2008 Dec; 130(6):1091-103. PubMed ID: 18987874
[TBL] [Abstract][Full Text] [Related]
15. Pathological angiogenesis and inflammation in tissues.
Jeong JH; Ojha U; Lee YM
Arch Pharm Res; 2021 Jan; 44(1):1-15. PubMed ID: 33230600
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenesis: Opening a new window for immunotherapy.
Guo F; Cui J
Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
[TBL] [Abstract][Full Text] [Related]
17. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment.
Kim HJ; Ji YR; Lee YM
Arch Pharm Res; 2022 Jun; 45(6):401-416. PubMed ID: 35759090
[TBL] [Abstract][Full Text] [Related]
19. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
20. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
Hameed S; Bhattarai P; Dai Z
Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
